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Introduction {#sec1}
============

*Staphylococcus aureus* is a ubiquitous organism that both colonizes human skin as an innocuous component of the commensal flora and causes invasive infection. The many surface proteins and toxins expressed by *S. aureus* that contribute to its ability to cause skin infection have been well characterized ([@bib11]), as has the inflammatory response that these proteins elicit. Less well understood is how *S. aureus* adapts to the human skin and maintains a state of chronic colonization and infection. To determine how *S. aureus* adapts to human skin, we studied a collection of isolates from children with atopic dermatitis (AD) who are colonized and repeatedly infected with *S. aureus* ([@bib13], [@bib23], [@bib29]). Although many host factors have been found to contribute to *S. aureus* infection in AD ([@bib14], [@bib17], [@bib25]), we were interested in determining the changes in the organisms that are associated with the ability to adapt to skin. Specific *S. aureus* clonal complexes, *agr* genotypes, and virulence factors have not been consistently linked to the pathogenesis of infection or colonization in AD ([@bib3], [@bib9], [@bib11], [@bib34]). The activation of a robust inflammatory response mediated by interleukin (IL)-1β is thought to be important in the clearance of *S. aureus* skin infection ([@bib19]), but the contribution of specific proinflammatory toxins or surface proteins has not been linked to these infections.

The metabolic pathways used by *S. aureus* in the context of human skin are closely linked to inflammation. Immune cells as well as keratinocytes rapidly alter their metabolic activities upon bacterial stimulation using glycolysis to generate ATP and induce hypoxia-inducible factor (HIF) 1α, an important metabolic and proinflammatory transcription factor ([@bib28]). *S. aureus* must use glycolysis and stimulate keratinocyte glycolysis to establish skin infection as demonstrated by the inability of Δ*pyk* mutants that are defective in glycolysis to infect skin ([@bib31], [@bib33]). Staphylococcal induction of keratinocyte glycolysis, even in the absence of toxin production, is sufficient to induce HIF1-α signaling and production of pro-IL-1β, a major proinflammatory cytokine ([@bib33]). Activation of the inflammasome and IL-1β production in epithelial stem cells has been associated with epigenetic changes that confer protection from secondary challenge ([@bib22]). This epigenetic reprogramming may be mediated by HIF-1α signaling ([@bib7]) and fumarate accumulation that modifies histone deacetylase activity and amplifies the cytokine response upon reinfection ([@bib1]). Murine skin infection with virulent *S. aureus* confers local protection from reinfection at the same site, due in part to increased macrophage populations in the skin that become primed and confer protective immunity to subsequent infection ([@bib5], [@bib6]). We postulated that the organisms associated with infection and colonization in patients with AD are selected for their ability to evade local immune clearance mechanisms and that this selective process involves metabolic adaptation to the skin.

In the studies detailed in this report, we characterized a group of 10 *S. aureus* isolates associated with chronic colonization or infection from patients with AD. Although no consistent changes in the genes associated with pathogen-associated molecular pattern or toxin expression were found, there was a striking accumulation of genetic polymorphisms or variants and changes in expression of genes that affect the tricarboxylic acid (TCA) cycle enzymes and terminal electron acceptors, metabolic changes that were found to have important immunological consequences.

Results {#sec2}
=======

*S. aureus* Isolates Adapted to Human Skin Are Genotypically Diverse {#sec2.1}
--------------------------------------------------------------------

From a collection of 134 *S. aureus* strains isolated from 79 patients, we selected 10 isolates from patients with the five highest and five lowest Eczema Area and Severity Index (EASI) scores as representing strains that had adapted to human skin. These skin-adapted strains (AD 1--10) were used for whole-genome sequencing, transcriptomic analysis, and phenotypic analysis ([Table 1](#tbl1){ref-type="table"}). Screening assays for selected virulence factors indicated substantial heterogeneity and a lack of correlation with clinical score. All the skin-adapted strains contained genes encoding many major toxins and adhesins, including *hla*, fibronectin-binding protein, and clumping factor ([Figure 1](#fig1){ref-type="fig"}A). The *hla* gene was present in all isolates, whereas in AD3, the gene contained a premature stop codon, which correlated with decreased Hla expression ([@bib26]). AD3 and AD6 also lacked genes for the leukotoxin LukED. Genes for *arcA-*ACME, *speG*-ACME*, lukF*-PVL, and *lukS*-PVL were not present in any of these isolates, suggesting that none of the clinical isolates had the classical suite of accessory genes found in many USA300 strains. Whole-genome phylogenies were constructed using both SNP-based and amino acid-based approaches along with 30 previously sequenced, publically available isolates to contextualize genetic diversity ([Figure 1](#fig1){ref-type="fig"}B, [Data S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). The results of the phylogenetic analysis, which agreed with clonal complex groupings as determined from multilocus sequence typing (MLST), showed a sporadic distribution mostly among CC8, CC1, and CC5, without clustering by clinical EASI score.Table 1Characteristics of *S. aureus* Strains Isolated from Patients with Atopic DermatitisIsolate \#EASI\
ScoreCulture SiteBacterial BurdenMRSA?MLST(CC; *spa* Type)Antibiotic ResistanceLow EASIAD14.5SFewMSSAST8(CC8; t1892)EMAD20.2SModerateMSSAST1(CC1; t922)AD32.4PModerateMRSAST22(CC22; new)OXAD43.1NFewMSSAST5 (CC5; t002)EMAD52SModerateMSSAST15(CC15; new)EMHigh EASIAD633.3SHeavyMSSAST9 (CC109; t209)EMAD733.6SFewMSSAST? (CC188; t189)AD840SHeavyMSSAST5 (CC5; t045)AD928.5SFewMRSAST8 (CC8; t008)CM, EM, LVX, OX, TCAD1040SHeavyMSSAST? (CC6; new)EM[^6][^7][^8]Figure 1*S. aureus* Strains Isolated from Patients with Atopic Dermatitis Are Diverse(A) Variable presence of toxin, resistance, and adhesion-associated genes. Heatmap display of Basic Local Alignment Search Tool (BLAST) results for specific gene sequence presence in each isolate compared with the reference strain USA300 FPR3757. Sequence identity (%) presented in KEY (right).(B) Maximum likelihood phylogenetic tree from a concatenated open reading frame dataset, rooted with SaMSHR1132 (branch not shown). Bacterial isolates from patients with atopic dermatitis analyzed with 30 previously sequenced "sign-post" genomes that are publicly available. Values on or near the node are bootstrap support percentages; values of 100% are indicated with a red circle. The branch length reference is in substitutions/site.See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Data S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

Skin-Adapted *S. aureus* Strains Have Variants in Metabolic Genes {#sec2.2}
-----------------------------------------------------------------

Whole-genome sequence data were analyzed to determine if adaptation to skin was reflected in the selection of specific mutations or variants ([Figures 2](#fig2){ref-type="fig"}A--2D). When compared with the sequence of the well-studied reference genome USA300 FPR3757, each of the clinical isolates had numerous nonsynonymous SNPs for key components of the TCA cycle, the glycolytic pathway, or terminal components of the electron transport chain, sites of mutation typically present in staphylococcal small-colony variants (SCVs) ([@bib24]) ([Figures 2](#fig2){ref-type="fig"}A and 2B). As a way to establish the novelty of the SNPs that we identified, we used a Gene Novelty Unit (GNU) score to determine how many times a specific protein variant had been previously identified in all available annotated *S. aureus* genomes in the database (8,524 genomes available at NCBI) ([Figures 2](#fig2){ref-type="fig"}C and 2D). The proteins from each isolate were matched with the *S. aureus* database, and each protein given a score (GNU score) that is the number of exact matches in the entire database. We asked how abundant each of the variants in metabolic genes identified in our clinical strains was in the entire database and generated a heatmap based on the GNU score for each metabolic protein ([Figure 2](#fig2){ref-type="fig"}C). We observed that some were entirely novel (GNU score = 0), whereas others were found repeatedly in the isolates in the database (GNU score \> 7,000). This analysis highlights several sequence variants that are completely new as well as proteins that have higher levels of novelty (lower GNU scores) overall, especially those in the terminal components of the electron transport chain and those involved in the succinate-fumarate axis. There was a striking number of nonsynonymous sequence polymorphisms and novel protein variants involved in bacterial handling of oxidant stress, namely, the SCV-associated menadione genes, *fumC,* and *fba* encoding aldolase in the glycolytic pathway, which is involved in the production of glyceraldehyde 3-phosphate (glyceraldehyde-3P). Glyceraldehyde-3P is a product of the pentose phosphate shunt, a substrate for glycolysis, and an important source of the anti-oxidant NADH. Note that the presence of SNPs or novel protein variants does not necessarily reflect loss of function, but may in fact be associated with increased or decreased expression and function of that locus. Although we did note many SNPs and novel protein variants in menadione, *hem*, and *mqo* loci, these were not associated with obvious growth defects. The lack of growth defects is not unexpected as these strains were recovered from the clinical microbiology laboratory, which was less likely to identify SCVs under their routine culture conditions given the ability of SCVs to rapidly revert to a wild-type (WT) phenotype ([@bib2], [@bib30]). The SNPs and protein variants identified in known SCV genes were more heterogeneous in the database ([Figure 2](#fig2){ref-type="fig"}C), suggesting that these are not likely novel to our clinical isolates.Figure 2Skin-Adapted Isolates Harbor Metabolic Gene Variants(A) Diagram of glycolysis and TCA cycle.(B) Heatmap of number of nonsynonymous SNPs in skin-adapted isolates in TCA cycle, glycolytic, and SCV genes compared with the reference strain USA300 FPR3757.(C) Heatmap of genes from 2B showing GNU score (number of exact protein matches \[100% identity and 100% coverage\]) in all known 8,524 *S. aureus* proteomes (as of 01/14/2019). Genes with 0 protein matches are indicated with a white asterisk.(D) Ten histograms of GNU scores from 2C of all the proteins in each isolate. The x axis indicates the GNU score within a bin of 100 GNU scores in the *S. aureus* database, and the y axis indicates the number of proteins in the isolate\'s genome with a certain GNU score.(E) qRT-PCR of TCA cycle genes in clinical *S. aureus* strains grown to exponential phase in lysogeny broth compared with USA300 WT LAC (representative graph of three individual experiments, n = 3 per condition). See also [Table S3](#mmc1){ref-type="supplementary-material"}.(F) Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of uninfected HEKn cells and those stimulated with WT USA300 JE2 and *fumC* transposon mutant.(G) Fumarate levels measured in cell media after 5-h infection in HEKn cells and associated cytotoxicity.Each data point is the mean value ±SEM (n = 3) \*p \< 0.05, ∗∗p \< 0.01, and \*\*\*\*p \< 0.0001 by one-way (F) or two-way ANOVA (E).

To put the GNU scores of these genes into the context of the entire genome and to get a sense of how many proteins in the genome have a similar number of exact hits, we plotted GNU score histograms with the y axis displaying the number of proteins in the genome that have matches in the databases within a bin of 100 GNU scores. Thus, for the 10 skin-adapted isolates that we analyzed, all had variants in metabolic genes that were very novel with GNU scores of \<50 ([Figure 2](#fig2){ref-type="fig"}D). We interpret this finding as an indication that such novel variants are more abundant in our collection of *S. aureus* from the skin, when compared with all the isolates from diverse sites that are represented in the database.

Eight of 10 skin-adapted strains had SNPs in *fumC* compared with USA300 and all 10 isolates had lower GNU scores at this locus; 5 of 10 were variants seen in less than 500 strains in the database, and the other 5 were present in less than 3,000 of 8,524 annotated genomes available at NCBI ([Figures 2](#fig2){ref-type="fig"}B and 2C). FumC was of interest as we noted its dramatic upregulation in our clinical isolates ([Figure 2](#fig2){ref-type="fig"}E) along with *S. aureus* isolates associated with chronic pulmonary infection ([@bib10]). Moreover, SNPs in genes involved in succinate metabolism (*sucA, B, C, D*), immediately upstream of fumarate in the TCA cycle, were present in 8/10 of the clinical strains from skin. Of these, 3 were completely novel protein variants in the SucA enzyme ([Figure 2](#fig2){ref-type="fig"}A) that converts α ketoglutarate into succinyl CoA, the succinate, and hence fumarate, precursor. The clinical isolate AD3 also had a completely novel protein sequence for SdhA, the enzyme that catalyzes the conversion of succinate to fumarate.

The variants that we identified could be associated with either increased or decreased gene expression. The *fumC* locus was upregulated in 7/10 isolates by 1,000--100,000 fold compared with USA300 ([Figure 2](#fig2){ref-type="fig"}E). Fumarate can suppress glycolysis by binding glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ([@bib16]), a key component of the glycolytic pathway generating pyruvate from glucose. Increased *fumC* expression would limit fumarate production and facilitate glycolysis, which is required for *S. aureus* proliferation in skin ([@bib33]). This was confirmed by demonstrating that a *fumC* mutant was associated with less induction of glycolysis in keratinocytes *in vitro* ([Figure 2](#fig2){ref-type="fig"}F) and significantly greater accumulation of fumarate, but no apparent effects on cytotoxicity ([Figure 2](#fig2){ref-type="fig"}G). Thus, it appears that a major selective pressure for *S. aureus* adaptation to skin is metabolic as a result of its need to use glycolysis to generate ATP and may account for increased *fumC* expression in some strains as well as the numerous polymorphisms in other genes involved in the TCA cycle.

Genetic Changes Associated with Metabolic Adaptation Variably Impact Cytokine Induction {#sec2.3}
---------------------------------------------------------------------------------------

Given the metabolic genetic variants found in the skin isolates, we sought to determine the nature of the immune responses elicited in host keratinocytes and the association with glycolysis. We confirmed that three representative skin-adapted *S. aureus* strains and a USA300 control activate keratinocyte glycolysis ([Figure 3](#fig3){ref-type="fig"}A), a response attributed chiefly to keratinocyte metabolism ([Figure 3](#fig3){ref-type="fig"}B). The stabilization of HIF1α was stimulated by each of the *S. aureus* strains tested ([Figure 3](#fig3){ref-type="fig"}C). The IL-1 cytokines, IL-1β, IL-1α, IL-1RA, and IL-18, were each significantly suppressed in the absence of glycolysis ([Figure 3](#fig3){ref-type="fig"}D), an effect that was not due to cytotoxicity ([Figure 3](#fig3){ref-type="fig"}E) or differences in the uptake of the various strains by the keratinocytes ([Figure 3](#fig3){ref-type="fig"}F). The expression of the proinflammatory cytokines tumor necrosis factor (TNF)-α and IL-8, seemed to be compensatory, as their production was increased in keratinocytes treated with 2-deoxyglucose (2-DG). Induction of the monocyte or macrophage-specific cytokines and IL-17A was not dependent on glycolysis. Although we observed statistically significant differences in cytokine induction by the various strains, the biological relevance of these differences remains to be established.Figure 3Skin-Adapted Strains Depend on Glycolysis to Stimulate Inflammatory Responses in Keratinocytes(A and B) (A) OCR and ECAR of uninfected HEKns versus those stimulated with clinical AD strains and WT USA300 LAC *S. aureus* and (B) bacteria alone. Each data point is the mean value (n = 3) with \*p \< 0.05 by two-way ANOVA compared with WT.(C) Immunoblots showing Hif1α in HEKn cells exposed to *S. aureus* for 4 h.(D--F) (D) Cytokines measured by ELISA, and (E) cytoxicity and (F) intracellular persistence at 24 h in HEKn cells infected with *S. aureus* isolates and treated with and without 2-DG by lysostaphin protection assay. Each data point is the mean value ± SEM (n = 3 for cytotoxicity and cytokines, n = 9 for intracellular persistence), \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 by two-way ANOVA.

Metabolic Adaptation Impairs Protection against Secondary Infection {#sec2.4}
-------------------------------------------------------------------

A murine model of cutaneous infection was used to compare the pathogenicity of an AD isolate and the USA300 LAC control strain. We studied the responses to infection caused by strain AD3, which had increased *fumC* and *sucA* expression as well as a completely novel amino acid sequence in SucA. Having first established that AD3 and USA300 had similar *in vitro* growth rates ([Figure S1](#mmc1){ref-type="supplementary-material"}), we showed that both strains caused similar amounts of dermonecrosis and were cleared equally well over 10 days of infection ([Figures 4](#fig4){ref-type="fig"}A and 4B). AD3 elicited a significantly greater amount of TNFα, IL-4, and IL-5 ([Figure 4](#fig4){ref-type="fig"}C), the latter two cytokines being consistent with the Th2-skewed response characteristic of previous studies of strains from patients with AD ([@bib21]). Immune cell recruitment into the skin lesions was also equivalent ([Figure 4](#fig4){ref-type="fig"}D).Figure 4AD3 Generates Less Local Memory than USA300(A) Bacterial load after 5 (n = 10) and 10 (n = 5) days, and dermonecrosis area over 10 days in mice intradermally infected with WT LAC or clinical isolate AD3.(B) Images of mouse lesions after 5 days of infection.(C) Cytokine measurements from skin biopsies of the infected sites after 5 days measured by ELISA.(D) Immune cell recruitment 5 days after infection measured by fluorescence-activated cell sorting analysis. Results shown are pooled from two independent experiments.(E) Area of dermonecrosis in mice infected with PBS, WT LAC, or AD3, followed by re-challenge at day 28 with WT LAC.(F) Image of mouse lesions at day 33 from initial infection (5 days after challenge).Each data point represents a mouse, and lines show mean values ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001 determined by one- or two-way (E) ANOVA.

As the impact of the metabolic changes in the skin-adapted strains was not manifested in acute immunogenicity, we postulated that the accrued polymorphisms in metabolic genes might impact the generation of local immune memory affecting the induction of protection to a repeated infectious challenge. We compared the ability of WT USA300 and AD3 to induce local protective immunity against a secondary infection. Following complete resolution of the initial infection, caused by either USA300 LAC or AD3, the animals were re-challenged at the same site with WT USA300. Mice primed with WT USA300 infection developed memory and had minimal lesions upon re-challenge, whereas those initially infected with AD3 had significantly larger areas of dermonecrosis upon USA300 re-challenge ([Figures 4](#fig4){ref-type="fig"}E and 4F). Thus the genetic differences in AD3 likely impact the generation of local protection to secondary *S. aureus* challenge, even though the initial response to infection appears similar to a non-adapted USA300 strain.

Discussion {#sec3}
==========

Based upon the genotypic and phenotypic characterization of *S. aureus* from chronically colonized patients, these studies illustrate that *S. aureus* dependence upon glycolysis for proliferation within the skin may promote the selection of strains with metabolic changes that promote glycolysis. We identified the accumulation of polymorphisms in genes likely to enhance glycolytic activity, limit the generation of fumarate, and in one case, prevent the development of local memory to secondary challenge. Our clinical strains were not phenotypically different from the isolates described in other reports characterizing strains from patients with AD ([@bib4], [@bib8], [@bib15]), exhibiting substantial diversity and the presence of the genes encoding surface proteins and toxins typically associated with pathogenicity. However, genotypically, these isolates associated with chronic skin colonization or infection reflected a distinctive distribution of SNPs and protein variants in metabolic loci, many of which were not commonly found in the extensive collection of publically available *S. aureus* genomes. These multiple sequence variants in genes were associated with portions of the TCA cycle, as well as with loci involved in the production of terminal electron acceptors, including menadione and hemin loci, changes that are expected to promote glycolysis. Our analysis of protein variants from clinical isolates associated with skin colonization or infection compared with the *S. aureus* isolates in the NCBI suggests that the majority of the organisms in the database, which are unlikely to be skin adapted, rarely contain this same collection of variants in genes involved in succinate and fumarate metabolism and suggests that these variants are selected within the context of skin infection.

The *fumC* locus was targeted in the skin-associated *S. aureus* strains, and several of these isolates had protein variants that were infrequent in the *S. aureus* genomic database. Some of these protein variants were identified in strains with over 100-fold induction of *fumC* expression along with differences in gene expression in additional loci that contribute to succinate-fumarate homeostasis. The presence of these metabolic variants suggests that regulation of fumarate is especially important for *S. aureus* to persist in the skin, which is consistent with the *S. aureus* requirement for glycolysis to support its bioenergetic activity in the skin ([@bib31], [@bib33]). There are several possible roles for fumarate and *fumC* in *S. aureus* metabolism. The expression of *fumC* may be upregulated for fumarate utilization as a carbon source when glucose is limited ([@bib18], [@bib27]), or fumarate may function to decrease oxidant stress, as it increases glutathione, a major oxidant trap within the cell. Another possibility is that the SNPs identified in our isolates may result in FumC inactivation leading to upregulation of *fumC* expression by the host cell to compensate for fumarate accumulation within the cell. Most consistent with our findings is fumarate suppression of aerobic glycolysis by binding directly to GAPDH, which provides substrates for glycolytic metabolism ([@bib16]). Hence, increased *fumC* expression by *S. aureus* isolates may lead to increased fumarate hydrolysis and prevent suppression of glycolysis. Of note, fumarate is also associated with selective effects on CD4 versus CD8 T cell function and the induction of IL-4 production ([@bib12], [@bib20]), an immunological phenotype characteristic of AD ([@bib32]).

The reliance of *S. aureus* upon glycolysis for its bioenergetic needs in the setting of keratinocyte infection provides a unifying theme to help explain the diversity in the phenotypes and genotypes of strains associated with skin infection in humans. As previously established, staphylococcal induction of glycolysis is associated with the stabilization of HIF-1α and IL-1β production ([@bib33]). Although not all the proinflammatory genes activated in keratinocytes by *S. aureus* were influenced by glycolysis, the major members of the IL-1 family including IL-1β, an important factor in an effective response to skin infection ([@bib19]), were suppressed in the presence of 2-DG. Despite variability in the presence of toxin and other virulence genes, the inherent immunostimulatory response to *S. aureus* induction of glycolysis was sufficient to activate a robust immune response. This helps to explain how even *agr* mutants and strains lacking toxins could be associated with AD flares ([@bib26]).

A major goal of this study was to establish the genetic changes in *S. aureus* that facilitate chronic skin infection. We demonstrate that there are metabolic changes in skin-adapted strains that function to promote staphylococcal glycolytic activity. We compared two unrelated strains with distinct phenotypes, a skin-adapted AD strain and a virulent USA300 LAC, which both activated similar immune responses and dermonecrosis, but had very different metabolic profiles. Although *S. aureus* is highly adapted to evade host immune responses, our studies indicate that adaptation to the local metabolic milieu is also important in the skin. Numerous epithelial and immune defects may contribute to the susceptibility of patients with AD to *S. aureus* infection. Our data indicate that the ability of *S. aureus* to adapt to the metabolic conditions imposed by skin is critical in establishing *S. aureus* colonization as well as susceptibility to reinfection.

Limitations of the Study {#sec3.1}
------------------------

Comparing clinical strains genotypically is limited by the difficulty in establishing an appropriate reference strain for each clinical isolate, and thus the variability in the genotypic background cannot be entirely accounted for, which is why we developed a GNU score to better appreciate the significance of the SNPs identified in these strains. The phenotypic analysis of local immune memory was limited by using two strains with varying genetic backgrounds, and thus we can postulate but cannot deduce that the differing response is due to metabolic differences between a skin-adapted and WT strain.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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